Confidential · Series A · $15M
The brain is the last unmeasured
vital system in the human body.
This is not a better brain scan. It is a claim on the infrastructure layer of neurological medicine — the platform that every clinician, health system, pharma company, and longevity programme will eventually run on.
Spryson was founded on an acquisition — a 30-year-old neurological technology platform with over $20M invested in its development, five FDA clearances, 30+ patents, and 350 existing customers, repositioned in 2024 as the neurological intelligence platform it was always capable of becoming.
Spryson is already FDA-cleared, already generating revenue, and already deployed at scale. The dataset is accumulating. The moat is compounding.
Proven · 2024–2026
—Platform built, validated and deployed
—Scalable product design and manufacturing established
—Reimbursement pathways established
—20+ pioneer clinician network active
—Gen 2 FDA claims filed — Parkinson's, Alzheimer's, MS
—Operationally self-sustaining
Scaling · 2026–2028 · $15M
—500+ customers
—AI platform launched
—Consumer platform piloted
—Rx product development initiated
—Gen 2 FDA claims advanced — vestibular migraine, fall prevention, dizziness & vertigo, anxiety & depression
—Distribution — Singapore, Japan, Brazil, UK
—Launch subscription model
—Path to $24M+ ARR
Beyond · Platform
—Rehabilitation referral network
—Consumer platform launched
—Pharma partnerships & companion diagnostics confirmed
—6 regulatory environments, one platform
—Pharma data licensing
Investment Snapshot · 2-minute read
The investment case
Enough to know if this warrants a deeper conversation.
Open →
Investor Overview · 5-minute read
The complete story
The full narrative — story, platform, verticals, data engine, investment case, indication pipeline, international expansion, and the 18–24 month vision.
Open →
Investor Presentation
The full deck — 33 slides
The complete investor presentation — platform architecture, financial model, indication pipeline, market opportunity, and the full data asset thesis.
Open →
Foundational document
The Nura Brain Performance Model
The scientific foundation of the platform — seven functional systems, 74 performance scores, one Brain Performance Profile. Available to qualified investors on request.
From the founder
01 · 2 minutes
The Future of Brain Health
The scale of the moment — why neurological disease is medicine's largest unmet need, why the window is now, and why the infrastructure platform that solves it does not yet exist.
02 · 2 minutes
Why Spryson Is Ready
The de-risked argument — FDA-cleared, revenue-generating, 350 customers, proven technology. This is not a pre-revenue bet. Everything an investor needs to believe is already true.
03 · 2 minutes
The Most Valuable Dataset Nobody Is Building
The data thesis — what one million neurological patient records is worth, why pharma pays for it, and why this compounds into the infrastructure layer of brain health globally.
04 · 2 minutes
Who Uses Spryson — and Why It Changes Everything
Eight people, eight moments — the worried patient, the GP, the neurologist, the pharma researcher, the longevity clinic — and how one platform changes the experience for all of them.
Three billion people. One platform.
The brain health infrastructure of the 21st century.
To arrange a conversation
Rob Adelson, CEO